Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa
May 15
Show Filter
08:00 - 08:50 50 mins
Registration
08:50 - 09:00 10 mins
Opening remarks from the Chairperson
  • Mélanie Thill-Tayara - Antitrust/Competition Partner, Dechert LLP, France
more
09:40 - 10:40 60 mins
INTERACTIVE DISCUSSION FORUM: Reverse payment patent settlements
  • David Hull - Partner, Van Bael & Bellis, Belgium
  • Ingrid Vandenborre - Partner, Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates, Belgium
  • Brian Sher - Partner, CMS, UK
  • Ann Pope - Senior Director (Antitrust), Competition and Markets Authority, UK
more
  • Latest developments and lessons learnt including but not limited to the following case law: Lundbeck and Servier
  • What are the lessons learnt from originator and generics companies?
10:40 - 11:10 30 mins
Morning coffee and networking break
11:10 - 12:10 60 mins
CASE LAW ROUNDUP: Excessive pricing, discounts and rebates in the pharmaceutical industry
  • James Killick - Partner, White & Case LLP, Belgium
  • Ingrid Vandenborre - Partner, Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates, Belgium
  • Jacob Westin - Legal Counsel, Shire, Sweden
more
  • Current status of abusive dominance through excessive pricing in the pharmaceutical industry
  • Decisions and developments including but not limited to the following case law: Aspen, Pfizer, Flynn Pharma
  • Examining approaches NCAs are taking
  • Reviewing decisions on pricing and rebates
12:10 - 12:50 40 mins
Recent EU merger control cases in the pharmaceutical industry
  • Rositsa Pencheva - Case Handler, DG Competition, European Commission, Belgium
  • Miranda Cole - Partner, Covington & Burling, Belgium
  • Satyen Dhana - Partner, Simmons & Simmons
more
  • Reviewing latest high profile cases
  • EU Commission’s innovation theory of harm
  • Exploring the key issues and pitfalls
  • Future developments
12:50 - 14:20 90 mins
Networking lunch
14:20 - 14:55 35 mins
Off-label use and drug repurposing in the EU: competition law considerations
  • Andrea Bazzotti - Senior Legal Advisor, Celgene International, Switzerland
more
  • Opportunities and concerns for off-label use
  • Reimbursement policies for off-label use including Italian and French legislation
14:55 - 15:30 35 mins
Examining parallel trade: Imports and exports
  • Maarten Meulenbelt - Partner, SIDLEY AUSTIN LLP, Brussels
more
  • Update on the Spanish dual pricing system and related case law
  • National responses to parallel trade-driven shortages
  • Jurisdiction of competition authorities
15:30 - 16:00 30 mins
Afternoon Coffee and Networking
16:00 - 17:30 90 mins
INTERACTIVE DISCUSSION FORUM: Lifecycle management with respect to competition law, patents and regulatory frameworks
  • Claudia Desogus - Officer, Italian Antitrust Authority, Italian Competition Authority
  • Kyriakos Fountoukakos - Partner, Herbert Smith Freehills LLP, Belgium
  • Glyn Truscott - Partner – UK & European Patent Attorney, Elkington + Fife, UK
  • Livia Zamfiropol - Partner, DLA Piper, Romania
more
  • Roche/Novartis case
  • Pfizer case in Italy: The notion of abuse of rights
  • How can you use IP legitimately and not fall foul?
  • Avoiding pitfalls with IP and regulatory strategies
17:30 - 17:35 5 mins
Chair's closing remarks and end of competition day
18:15 - 20:15 120 mins
EVENING SEMINAR A: Brexit: Implications for the Pharmaceutical Industry
  • Anneli Howard - Barrister, Monckton Chambers, UK
  • Peter Bogaert - Partner, Covington & Burling LLP, Belgium
  • Natasha Pearman - Managing Associate, Mishcon de Reya LLP, UK
  • Jonathan Mogford - Director of Policy, MHRA, UK
more

18:15 Registration • 18:30 Start • 20:15 Networking Dinner


Topics to be discussed will include:

  • Latest status and timelines for Brexit as of May 2018
  • Update on the relocation of the EMA and implications for industry
  • Discussing the impact of Brexit on:
  • Regulatory frameworks in the UK and across Europe
  • Pricing and reimbursement
  • Pharmacovigilance
  • Competition law obligations
  • Relocation of the UPC
  • A practical checklist approach for preparing for Brexit
Next Stream 1: Intellectual Property Stream 2: Regulatory Frameworks  Wednesday, 16 May 2018
This site uses cookies to improve the Informa Life Sciences experience.